Avalo Therapeutics, Inc. (AVTX) Reports FY Loss of $114.00
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AVTX Hot Sheet
Join SI Premium – FREE
Avalo Therapeutics, Inc. (NASDAQ: AVTX) reported FY EPS of ($114.00). Revenue for the year came in at $1.92 million.
For earnings history and earnings-related data on Avalo Therapeutics, Inc. (AVTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- Genco Shipping & Trading Limited (GNK) Misses Q3 EPS by 5c
- Clover Health Investments (CLOV) Tops Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
